The identification of the estrogen receptor and its role in breast cancer development has driven the advancement of endocrine therapies. To maximize outcomes for patients with HR+/HER2- metastatic breast cancer, members of the of the multidisciplinary team must stay informed about the latest endocrine therapy options and combinations. This educational program aims to improve participants' competence in using these therapies, analyzing molecular mutations and biomarkers, and selecting the most appropriate treatment for each patient. Through animated graphical imagery, videos, and didactic learning, faculty will explore the clinical application, efficacy, safety, and administration of these therapies. Real-world case studies will illustrate how these therapies may be used in HR+/HER2- metastatic breast cancer and equip learners with the knowledge to personalize treatment and address endocrine resistance effectively.

RELEASED DATE: July 07, 2025
EXPIRATION DATE: July 07, 2026

This concise podcast, part of a three-part series, features expert faculty discussing endocrine therapies for HR+/HER2- metastatic breast cancer and their optimal sequencing in clinical practice. Key topics include managing disease progression on CDK4/6 inhibitors, exploring combination therapies (eg, oral SERDs with CDK4/6 inhibitors), strategies for treatment sequencing and switching, and evaluating the clinical utility of ctDNA assays. Designed for healthcare professionals, this episode delivers practical insights to enhance patient care.

RELEASED DATE: June 27, 2025
EXPIRATION DATE: August 01, 2026

In this breast cancer grand rounds program, faculty will discuss current and emerging endocrine therapies for patients with HR+/HER2- metastatic breast cancer by reviewing clinical trials, treatment algorithms, and the currently available treatments for this type of cancer. Additionally, the speakers will discuss concepts in molecular testing and analysis of mutations to help inform treatment selection in this population.

RELEASED DATE: July 10, 2025
EXPIRATION DATE: July 10, 2026

The identification of the estrogen receptor and its role in breast cancer development has driven the advancement of endocrine therapies. In this enduring educational activity, expert faculty will examine the clinical application, efficacy, safety, and administration of these therapies for HR+/HER2- metastatic breast cancer. Through a case-based approach, participants will engage with real-world scenarios to understand tailored treatment strategies and approaches to overcoming endocrine resistance.

RELEASED DATE: July 18, 2025
EXPIRATION DATE: July 18, 2026

The identification of the estrogen receptor and the role it has in the development of most breast cancers has led to the development of endocrine therapies. In this enduring program, the faculty will explore these therapies with regard to clinical usage, efficacy, safety, and administration. This case-based program will allow participants to experience real-life examples of how these therapies may be used for HR+/HER2- metastatic breast cancer and inform learners how to tailor treatment individually and overcome endocrine resistance.

RELEASED DATE: September 12, 2025
EXPIRATION DATE: September 12, 2026